SavedAdd your journal

Journals / Gazi Medical Journal / 2013 / Cilt: 24 - Sayı: 2

Neuroleptic malignant syndrome associated with metoclopropamide in a patient with metastatic gastric carcinoma

Metastatik gastrik karsinomlu bir olguda metoklopropamid ilişkili nöroleptik malign sendrom

Süleyman BÜYÜKBERBER
Umut DEMİRCİ
Meltem BAYKARA
Efnan ALGİN
Gülnihal TUFAN
Burçak CAVNAR
Uğur COŞKUN
Mustafa BENEKLİ
Pages
53–54
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It occurs due to blockade of dopamin receptors by metoclopropamid in brain and high cholinergic stimulation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome (NMS) is a rare syndrome which can be fatal and characterized by hyperthermia, muscular rigidity, changes in consciousness, autonomic dysfunction, increased serum creatinine kinase and leukocytosis.
📊
Key Findings & Data:We present a case with metastatic gastric cancer developed neuroleptic malignant syndrome after metoclopropamide treatment.Metoclopropamide-associated neuroleptic malignant syndrome is a rare life-threatening condition.
💡
Conclusion & Impact:It occurs due to blockade of dopamin receptors by metoclopropamid in brain and high cholinergic stimulation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome (NMS) is a rare syndrome which can be fatal and characterized by hyperthermia, muscular rigidity, changes in consciousness, autonomic dysfunction, increased serum creatinine kinase and leukocytosis. We present a case with metastatic gastric cancer developed neuroleptic malignant syndrome after metoclopropamide treatment.Metoclopropamide-associated neuroleptic malignant syndrome is a rare life-threatening condition. It occurs due to blockade of dopamin receptors by metoclopropamid in brain and high cholinergic stimulation.

Özet

Nöroleptik Malign Sendrom (NMS), hipertermi, müsküler rijidite, şuurdeğişikliği, otonomik disfonksiyon, serum kreatinfosfokinaz (CPK)düzeyinde yükselme ve lökositoz ile karakterize olup; nadir görülen ve fatalseyredebilen bir sendromdur. Metoklopropamid ilişkili NMS nadir fakathayatı tehtid eden bir durumdur. Metoklopropamid ilişkili NMS,metoklopropamidin beyindeki dopamin reseptörlerini bloke etmesi vegüçlü kolinerjik stimulasyon etkisi sonucu ortaya çıkmaktadır. Biz buradametastatik mide kanseri tanısıyla takip edilirken emezis nedeniylemetoklopropamid kullanımı sonrasında NMS gelişen bir olguyu sunuyoruz.

🔖

Cite This Article

BÜYÜKBERBER, S., DEMİRCİ, U., BAYKARA, M., ALGİN, E., TUFAN, G., CAVNAR, B., COŞKUN, U., BENEKLİ, M. (2022). Neuroleptic malignant syndrome associated with metoclopropamide in a patient with metastatic gastric carcinoma. Gazi Medical Journal, Cilt: 24 - Sayı: 2, 53–54. https://ajindex.com/articles/520150

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Robinson MB, Kennett RP, Harding AE, Legg NJ, Clarke B. Neuroleptic malignant syndrome associated with metoclopramide. J Neurol Neurosurg Psychiatry 1985
  2. Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008
  3. Norris B, Angeles V, Eisenstein R, Seale JP. Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. Ann Pharmacother 2006
  4. Norgard NB, Stark JE. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 2006
  5. Knight ME, Roberts RJ. Phenothiazine and butyrophenone intoxication in children. Pediatr Clin North Am 1986
  6. Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984
  7. Kawanishi C, Onishi H, Kato D, Yamada T, Onose M, Hirayasu Y. Neuroleptic malignant syndrome in cancer treatment. Palliat Support Care 2005
  8. Spivak B, Gonen N, Mester R, Averbuch E, Adlersberg S, Weizman A. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 1996
  9. Tanii H, Fujita K, Okazaki Y. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal. Am J Psychiatry 2006
  10. Patterson J F. Neuroleptic malignant syndrome associated with metoclopramide. Southern Medical Journal 1988
  11. Cassidy T, Bansal SK. Neuroleptic malignant syndrome associated with metoclopramide. British Medical Journal 1988
  12. Krähenbühl S, Raisin J, Herren T. Malignant neuroleptic syndrome under metoclopramide and neuroleptics in anuria. Schweiz Med Wochenschr 1993
  13. Bakri YN, Khan R, Subhi J, Kawi Z. Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. Gynecol Oncol 1992
  14. Brower RD, Dreyer CF, Kent TA. Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy related nausea. J Child Neurol 1989
  15. Sanai T, Matsui R, Hirano T, Torichigai S, Yotsueda H, Higashi H, Hirakata H, Iida M. Successful treatment of six patients with neuroleptic malignant syndrome associated with myoglobulinemic acute renal failure. Ren Fail 2006
  16. Kasantikul D, Kanchanatawan B. Neuroleptic malignant syndrome: a review and report of six cases. J Med Assoc Thai 2006
  17. Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly u